271 related articles for article (PubMed ID: 37298520)
21. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
[TBL] [Abstract][Full Text] [Related]
22. Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma.
Przybyl J; Spans L; Ganjoo K; Bui N; Mohler D; Norton J; Poultsides G; Debiec-Rychter M; van de Rijn M
PLoS One; 2022; 17(1):e0262272. PubMed ID: 34986184
[TBL] [Abstract][Full Text] [Related]
23. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
24. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
25. Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.
Schöffski P; Lahmar M; Lucarelli A; Maki RG
Future Oncol; 2023 Mar; 19(9):621-629. PubMed ID: 36987836
[TBL] [Abstract][Full Text] [Related]
26. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334
[TBL] [Abstract][Full Text] [Related]
27. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797
[TBL] [Abstract][Full Text] [Related]
28. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
29. Double minute chromosomes harboring MDM2 amplification in a pediatric atypical lipomatous tumor.
Dadone-Montaudié B; Burel-Vandenbos F; Soler C; Rosello O; Boyer C; Fabas T; Bianchini L; Pedeutour F
Genes Chromosomes Cancer; 2019 Sep; 58(9):673-679. PubMed ID: 30887579
[TBL] [Abstract][Full Text] [Related]
30. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
Thirasastr P; Somaiah N
Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
[TBL] [Abstract][Full Text] [Related]
31. Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.
Dantey K; Schoedel K; Yergiyev O; Bartlett D; Rao UNM
Hum Pathol; 2017 Aug; 66():86-92. PubMed ID: 28300575
[TBL] [Abstract][Full Text] [Related]
32. Whole exome sequencing of well-differentiated liposarcoma and dedifferentiated liposarcoma in older woman: a case report.
Zhao Z; Chen X; Xu J; Shi Y; Mak TK; Huo M; Zhang C
Front Med (Lausanne); 2023; 10():1237246. PubMed ID: 37649981
[TBL] [Abstract][Full Text] [Related]
33. Well-differentiated and dedifferentiated liposarcomas.
Coindre JM; Pédeutour F; Aurias A
Virchows Arch; 2010 Feb; 456(2):167-79. PubMed ID: 19688222
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Ono T; Akiyama T; Iwata S; Sugaya J; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 May; 35(3):936-943. PubMed ID: 35292923
[TBL] [Abstract][Full Text] [Related]
35. Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Higuchi T; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(4):351-358. PubMed ID: 32576580
[TBL] [Abstract][Full Text] [Related]
36. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
37. [Paratesticular liposarcoma: the clinicopathological features of nineteen cases].
Yang SM; Wu RC; Qi SS; You JF
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):17-22. PubMed ID: 34979748
[No Abstract] [Full Text] [Related]
38. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
39. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
40. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR; Bauer S; Suarez C; Lin CC; Quek R; Hütter-Krönke ML; Cubedo R; Ferretti S; Guerreiro N; Jullion A; Orlando EJ; Clementi G; Sand Dejmek J; Halilovic E; Fabre C; Blay JY; Italiano A
Clin Cancer Res; 2022 Mar; 28(6):1087-1097. PubMed ID: 34921024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
